Affiliate disclosure: GLP1CostCalculator.com earns commissions from affiliate partners listed on this site. This article is editorial content written by our health cost reporter and is not influenced by advertiser relationships. Programs reviewed with FDA warning letters are disclosed with badges regardless of affiliate status.
Research note: This article draws on the FDA Warning Letters database (fda.gov), published regulatory guidance, KFF Health News cost analyses, and STAT News investigative reporting. All warning letter recipients named were confirmed via the FDA's public disclosure database. Patient accounts are drawn from interviews with compounded GLP-1 program users and are anonymized per our editorial policy.
If you have been using a compounded GLP-1 medication through a telehealth platform — or shopping for one — you have probably seen some version of this headline. The FDA sent warning letters to 30 telehealth companies in February 2026 for making misleading claims about compounded semaglutide and tirzepatide. The news spread fast, and understandably sent a lot of patients scrambling.
I want to be clear about what actually happened here, because the coverage has ranged from accurate to genuinely alarming in ways that do not reflect what the letters actually say.
I spent six years in insurance billing — specializing in prior authorization appeals for specialty medications including GLP-1 agents — before switching to health writing. I know this landscape from the inside: one of the last GLP-1 cases I worked on before leaving the billing role was a patient whose Ozempic prescription was denied four times over eight months despite an A1C of 9.4. The appeals required physician letters, metabolic panel results, and documented failure of two prior weight-loss medications. She was eventually approved — after her diabetes progressed enough to require hospitalization. That delay, her endocrinologist told me afterward, was avoidable. It is one reason I now write about how patients navigate this system rather than just processing claims within it.
In the weeks after this enforcement wave, I spoke with patients, pharmacy benefits managers, and one compounding pharmacist who dispenses to multiple telehealth platforms. The picture is more nuanced, and more manageable, than most coverage suggests.
What the FDA Actually Did
On February 20, 2026, the FDA's Center for Drug Evaluation and Research sent warning letters to 30 telehealth companies marketing compounded GLP-1 medications. The letters were made public March 3, 2026, alongside a statement from FDA Commissioner Marty Makary calling it a new era of enforcement. All issued letters are searchable in the FDA warning letter database at fda.gov.
The violations were almost entirely about advertising claims — specifically. The full list of issued letters with company response dates is publicly searchable in the FDA Warning Letters database under the "Drugs" category for 2026:
Sameness claims: Companies were saying things like "contains the same active ingredient as Ozempic" or "compounded semaglutide is the same as the brand-name drug." The FDA's position is that compounded drugs have not been evaluated for safety, effectiveness, or quality as finished products — so claiming equivalence to an FDA-approved drug is misleading under 21 U.S.C. section 352.
Sourcing opacity: Some companies branded products with their own name or trademark without making clear they were not the actual compounder. This creates confusion about accountability in the supply chain.
That is it. The FDA was not saying the medications were dangerous, was not issuing product recalls, and was not shutting down compounding pharmacies. Companies received 15 business days to respond with a corrective plan.
The Real Dollar Gap — Why Patients Use Compounded GLP-1s
Before discussing compliance, it is worth grounding why these programs exist at all. A patient I spoke with recently — on compounded semaglutide for 14 months — put it plainly: my doctor wanted me on Wegovy. My insurance denied it twice. The prior authorization alone took six weeks.
The numbers explain the market:
| Medication | Route | Monthly cost (without insurance) |
|---|---|---|
| Wegovy (branded semaglutide) | Injection | $1,349/mo |
| Ozempic (branded semaglutide, off-label weight use) | Injection | $935/mo |
| Compounded semaglutide (telehealth) | Injection | $96–$299/mo |
| Compounded semaglutide (telehealth) | Oral/sublingual | $125–$197/mo |
According to a 2024 KFF Health News analysis, fewer than 25% of commercially insured patients who receive a GLP-1 prescription actually fill it at retail — cost is the primary barrier. Compounded programs at $96–$200/mo represent a 78–93% reduction versus retail branded pricing. That gap is why 30 warning letters did not kill this market overnight.
I worked with a patient last year who had tried four times to get Wegovy covered. After the fourth denial, she enrolled in a compounded semaglutide program at $149/mo. Fourteen months later she had lost 47 pounds. The warning letter her provider received in February did not change any of that.
Why This Happened Now
The semaglutide shortage — which originally gave compounders legal standing to mass-market compounded versions — officially ended in early 2025. When a branded drug is in shortage, 503A compounding pharmacies have more legal latitude to compound at scale. Once that shortage designation lifts, the rules tighten significantly.
After the shortage ended, the FDA had been signaling enforcement since September 2025, when it launched a broader crackdown on misleading direct-to-consumer pharmaceutical advertising. Commissioner Makary's comments about Hims and Hers earlier in 2026 made the agency's posture clear: compounded drugs serve a legitimate purpose, but they cannot be marketed as interchangeable alternatives to FDA-approved products.
For tirzepatide (Mounjaro, Zepbound), the legal landscape remains more complicated — court injunctions have kept compounding access alive in practice even as the FDA pushes back. Multiple cases are still working through the courts as of this writing.
The FDA Enforcement Timeline
Early 2025 — Semaglutide shortage officially ends, removing the legal basis for large-scale compounding under shortage exemptions.
September 2025 — FDA launches crackdown on misleading direct-to-consumer pharmaceutical advertising. Warning letters go to large national players including Hims and Hers and Novo Nordisk.
February 4, 2026 — FDA publishes updated guidance on concerns with unapproved GLP-1 drugs used for weight loss, signaling the February enforcement wave.
February 20, 2026 — FDA sends 30 warning letters to telehealth companies. Confirmed recipients include Strut Health (Strut Health, LLC dba Strut) and SkinnyRx (Lean Rx, Inc. dba SkinnyRx).
March 3, 2026 — FDA makes warning letters public with Commissioner Makary's statement.
March 9, 2026 — Hims and Hers announces partnership with Novo Nordisk, exiting the compounded market entirely — the clearest indicator yet of how significant FDA pressure had become.
April–May 2026 — Multiple court injunctions continue to affect tirzepatide compounding. Enforcement against non-compliant companies ongoing.
Which Companies Were Named
The FDA's announcement did not release a full list immediately. Based on the FDA warning letter database and published reporting, confirmed recipients include Strut Health and SkinnyRx, alongside Newman Clinic PLLC. A STAT News analysis published March 2026 found at least 30% of the 70-plus companies warned by the FDA over six months share clinical affiliations with just four nationwide medical groups: Beluga Health, OpenLoop, MD Integrations, and Telegra.
"The marketing problem was predictable and preventable," said one licensed compounding pharmacist who fills prescriptions for two telehealth platforms and asked not to be identified by name given the ongoing enforcement environment. "The clinical model — telehealth intake, compounded medication, licensed pharmacist dispensing — is sound. It was the advertising that created the legal exposure, not the pharmacy side."
The common thread: marketing language implying their compounded products had been FDA-reviewed or were clinically equivalent to branded drugs.
What It Does Not Mean
It is not a product recall. The FDA did not order any compounded GLP-1 products pulled from the market.
It is not a shutdown. Companies that received letters and updated their marketing are still operating.
It is not proof the medications are unsafe. The warning letters focus entirely on advertising claims, not product quality or patient outcomes.
It is not the end of compounded GLP-1 access. The 503A compounding pathway remains intact for patient-specific prescriptions with documented clinical need.
Another patient I spoke with, a 52-year-old man managing type 2 diabetes alongside a weight management goal, had been on compounded tirzepatide for eight months through a program that later received a warning letter. His provider updated its website language within 10 days of the letter going public. His prescription continued without interruption. His A1C dropped from 8.1 to 6.7 in that period.
What to Do If Your Program Is on the Warning Letter List
If your program received a warning letter, take these five steps before making any changes to your medication:
- Do not stop your medication cold turkey. GLP-1 discontinuation can lead to rapid weight regain and appetite rebound. Discuss any changes with a licensed provider first.
- Check whether your provider has issued a compliance response. Companies had 15 business days to respond. Visit their website and look for updated language — removal of "same as Ozempic"-type claims is the clearest sign of compliance.
- Request your prescription documentation. Ask your provider to confirm your prescription includes specific clinical justification for compounded medication rather than the branded drug. This protects you in the event of further enforcement.
- Verify your compounding pharmacy's license. Your medication should come from a 503A state-licensed compounding pharmacy. Ask for the pharmacy name and verify their license through your state board of pharmacy website.
- Request a Certificate of Analysis (COA). Any legitimate compounding pharmacy can provide a third-party COA confirming potency and purity. If they cannot, that is a meaningful red flag regardless of the FDA letters.
Five Questions to Ask Your Current Provider
Use these as a direct checklist with your telehealth provider:
- What compounding pharmacy fills my prescriptions, and are they licensed and inspected by the state board of pharmacy?
- Does my prescription documentation include a specific clinical reason for compounded medication rather than the branded drug?
- Has your marketing and website language been updated to comply with FDA guidance issued in February 2026?
- Do your compounded products have third-party certificates of analysis (COAs) available?
- Who are the licensed physicians or nurse practitioners reviewing and approving prescriptions?
Any reputable telehealth provider should answer all five clearly. Vague answers or runaround on any of them is a signal worth taking seriously — regardless of whether they received a warning letter.
How We Screen Providers on This Site
I want to be transparent about how this affects the programs listed on GLP1CostCalculator.com.
We note FDA warning letter history directly in listings for programs that received letters, rather than pretending it did not happen. Our screening criteria include:
- Prescription verification: Every program requires a licensed provider consultation before prescribing — no auto-approval intake flows
- Pharmacy accountability: Medications ship from named, state-licensed U.S. compounding pharmacies
- Compliance posture: Programs that received warning letters are listed only if they have demonstrably updated their marketing claims
- COA availability: We ask whether third-party certificates of analysis are available on request
- Pricing transparency: No programs with hidden fees or subscription trap cancellation terms
For providers that received letters and have since updated their marketing to comply — and are still actively serving patients — we keep them listed with an FDA disclosure badge. For providers where corrective action has not been demonstrated, we remove them.
Every program we list is cash-pay, requires a licensed provider consultation before prescribing, and ships from licensed U.S. compounding pharmacies. None claim their products are FDA-approved, because they are not. Compounded medications are legal — they are just not the same thing as FDA-approved branded drugs, and our listings reflect that clearly.
If you are unsure about your current program, the questions and action steps above are a good place to start. Our comparison page lists programs we have independently reviewed with full pricing transparency, including FDA disclosure badges where applicable.
Sarah Mitchell covers GLP-1 costs, telehealth access, and insurance navigation for GLP1CostCalculator.com. She spent six years in insurance billing — specializing in prior authorization appeals for specialty medications including GLP-1 agents — before switching to health writing. She is not a licensed healthcare provider; nothing in this article constitutes medical advice. Consult your prescriber before making any changes to your medication.